AI’s role in insurance is already spawning lawsuits and battles over its regulation. That's not slowing down its use.

For the year ending December 31, 2025, the return for Rochon Global Portfolio was 2.7% vs. 13.7% for our benchmark, which ...

The company's Biomea that is the lead program, icovamenib, is the first in the category of menin inhibitors directed to the treatment of both type 1 and type 2 diabetes that holds the potential to ...

Social media sleuths found search results on the Uber Eats app returned restaurant recommendations based on anti-Black, ...